<p>Geode Capital Management LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中表示，在第四季度將其在 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免費報告）中的持倉增加了 1,600.1%。該公司在本季度額外購買了 1,855,907 股後，持有該公司 1,971,894 股股票。根據其最近向證券交易委員會（SEC）提交的文件，Geode Capital Management LLC 擁有 Tonix Pharmaceuticals 約 105.45% 的股份，價值 650,000 美元。</p>
<p>獲取 <strong>Tonix Pharmaceuticals</strong> 警報：</p>
<ul>
<li>製藥狂潮：波動性點燃生物技術行業</li>
</ul>
<p>另外，Commonwealth Equity Services LLC 在第四季度購買了 Tonix Pharmaceuticals 的新股份，價值 40,000 美元。目前 82.26% 的股票由機構投資者持有。</p>
<h2>分析師設定新目標價</h2>
<p>TNXP 一直是多份研究報告的主題。Noble Financial 在 3 月 20 日的報告中重申了 &#34;跑贏大盤&#34; 的評級，並對 Tonix Pharmaceuticals 的股票設定了 70.00 美元的目標價。StockNews.com 於 2 月 10 日的研究報告中開始覆蓋 Tonix Pharmaceuticals，並對該股票給予了 &#34;賣出&#34; 的評級。</p>
<ul>
<li>Tonix Pharmaceuticals 是下一個生物技術突破嗎？</li>
</ul>
<p><strong>查看我們對 Tonix Pharmaceuticals 的最新分析</strong></p>
<h2>Tonix Pharmaceuticals 股價上漲 10.9%</h2>
<p>週一，TNXP 的股價開盤為 20.00 美元。Tonix Pharmaceuticals Holding Corp. 的 52 周低點為 6.76 美元，52 周高點為 672.00 美元。該公司的債務與股本比率為 0.07，速動比率為 2.81，流動比率為 3.33。該公司的 50 日移動平均線為 16.88 美元，200 日移動平均線為 20.69 美元。該股票的市值為 1.287 億美元，市盈率為 0.00，貝塔值為 1.50。</p>
<p>Tonix Pharmaceuticals（NASDAQ:TNXP - 獲取免費報告）最後一次公佈財報是在 3 月 18 日，報告顯示該季度每股收益（EPS）為（9.77）美元，低於市場共識預期的（6.23）美元，差額為（3.54）美元。該季度的營業收入為 258 萬美元，而分析師的預期為 320 萬美元。Tonix Pharmaceuticals 的淨利潤率為負 1,197.86%，股本回報率為負 163.95%。賣方分析師預計 Tonix Pharmaceuticals Holding Corp. 在當前財政年度的每股收益將為 -1762.5。</p>
<h2>Tonix Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Tonix Pharmaceuticals Holding Corp. 是一家生物製藥公司，專注於開發、發現、商業化和許可治療人類疾病和減輕痛苦的治療藥物。它市場銷售 Zembrace SymTouch 和 Tosymra，用於治療成人急性偏頭痛（有或沒有先兆）。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Tonix Pharmaceuticals</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>西部數據：存儲行業是否準備反彈？</li>
<li>深入瞭解買賣差價</li>
<li>Wingstop 股票因第一季度業績超預期和擴張前景而上漲</li>
<li>三隻股票保護您的投資組合免受冠狀病毒傳播的影響</li>
<li>為什麼像埃克森美孚和赫斯這樣的能源股票重新受到關注</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>您現在應該投資 1,000 美元在 Tonix Pharmaceuticals 嗎？</h2>
<p>在您考慮 Tonix Pharmaceuticals 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Tonix Pharmaceuticals 並不在名單上。</p>
<p>雖然 Tonix Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Tonix 醫藥控股

<p>Geode Capital Management LLC 在第四季度將其在 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) 的持股比例增加了 1,600.1%，收購了 1,855,907 股，使其總持股達到 1,971,894 股，價值 650,000 美元。機構投資者持有該股票的 82.26%。分析師對 TNXP 設定的目標價為 70.00 美元，而該股票開盤價為 20.00 美元，52 周的價格區間為 6.76 美元至 672.00 美元。該公司報告上個季度每股虧損 9.77 美元，未能達到預期，並預計本財年每股虧損將達到 -1762.5 美元</p>

<p>Geode Capital Management LLC grew its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) by 1,600.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,971,894 shares of the company's stock after purchasing an additional 1,855,907 shares during the quarter. Geode Capital Management LLC owned approximately 105.45% of Tonix Pharmaceuticals worth $650,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Geode Capital Management LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中表示，在第四季度將其在 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免費報告）中的持倉增加了 1,600.1%。該公司在本季度額外購買了 1,855,907 股後，持有該公司 1,971,894 股股票。根據其最近向證券交易委員會（SEC）提交的文件，Geode Capital Management LLC 擁有 Tonix Pharmaceuticals 約 105.45% 的股份，價值 650,000 美元。</p>
</div><p>Get <strong>Tonix Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tonix Pharmaceuticals</strong> 警報：</p>
</div><ul>
<li>Pharma Frenzy: Volatility Ignites Biotech Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>製藥狂潮：波動性點燃生物技術行業</li>
</ul>
</div><p>Separately, Commonwealth Equity Services LLC bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth $40,000. 82.26% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>另外，Commonwealth Equity Services LLC 在第四季度購買了 Tonix Pharmaceuticals 的新股份，價值 40,000 美元。目前 82.26% 的股票由機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>TNXP has been the topic of a number of research reports. Noble Financial reiterated an &#34;outperform&#34; rating and issued a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a &#34;sell&#34; rating on the stock.</p>
<div class="lb-trans"><p>TNXP 一直是多份研究報告的主題。Noble Financial 在 3 月 20 日的報告中重申了 &#34;跑贏大盤&#34; 的評級，並對 Tonix Pharmaceuticals 的股票設定了 70.00 美元的目標價。StockNews.com 於 2 月 10 日的研究報告中開始覆蓋 Tonix Pharmaceuticals，並對該股票給予了 &#34;賣出&#34; 的評級。</p>
</div><ul>
<li>Is Tonix Pharmaceuticals the Next Biotech Breakout?</li>
</ul>
<div class="lb-trans"><ul>
<li>Tonix Pharmaceuticals 是下一個生物技術突破嗎？</li>
</ul>
</div><p><strong>View Our Latest Analysis on Tonix Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Tonix Pharmaceuticals 的最新分析</strong></p>
</div><h2>Tonix Pharmaceuticals Trading Up 10.9 %</h2>
<div class="lb-trans"><h2>Tonix Pharmaceuticals 股價上漲 10.9%</h2>
</div><p>Shares of TNXP opened at $20.00 on Monday. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $6.76 and a fifty-two week high of $672.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company's fifty day moving average is $16.88 and its 200 day moving average is $20.69. The stock has a market capitalization of $128.70 million, a PE ratio of 0.00 and a beta of 1.50.</p>
<div class="lb-trans"><p>週一，TNXP 的股價開盤為 20.00 美元。Tonix Pharmaceuticals Holding Corp. 的 52 周低點為 6.76 美元，52 周高點為 672.00 美元。該公司的債務與股本比率為 0.07，速動比率為 2.81，流動比率為 3.33。該公司的 50 日移動平均線為 16.88 美元，200 日移動平均線為 20.69 美元。該股票的市值為 1.287 億美元，市盈率為 0.00，貝塔值為 1.50。</p>
</div><p>Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The business had revenue of $2.58 million for the quarter, compared to analysts' expectations of $3.20 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Tonix Pharmaceuticals（NASDAQ:TNXP - 獲取免費報告）最後一次公佈財報是在 3 月 18 日，報告顯示該季度每股收益（EPS）為（9.77）美元，低於市場共識預期的（6.23）美元，差額為（3.54）美元。該季度的營業收入為 258 萬美元，而分析師的預期為 320 萬美元。Tonix Pharmaceuticals 的淨利潤率為負 1,197.86%，股本回報率為負 163.95%。賣方分析師預計 Tonix Pharmaceuticals Holding Corp. 在當前財政年度的每股收益將為 -1762.5。</p>
</div><h2>Tonix Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Tonix Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.</p>
<div class="lb-trans"><p>Tonix Pharmaceuticals Holding Corp. 是一家生物製藥公司，專注於開發、發現、商業化和許可治療人類疾病和減輕痛苦的治療藥物。它市場銷售 Zembrace SymTouch 和 Tosymra，用於治療成人急性偏頭痛（有或沒有先兆）。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Tonix Pharmaceuticals</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Western Digital: Is the Storage Sector Set for a Rebound?</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Wingstop Stock Jumps on Q1 Beat, Expansion Outlook</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>Why Energy Stocks Like Exxon and Hess Are Back in Focus</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Tonix Pharmaceuticals</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>西部數據：存儲行業是否準備反彈？</li>
<li>深入瞭解買賣差價</li>
<li>Wingstop 股票因第一季度業績超預期和擴張前景而上漲</li>
<li>三隻股票保護您的投資組合免受冠狀病毒傳播的影響</li>
<li>為什麼像埃克森美孚和赫斯這樣的能源股票重新受到關注</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNXP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tonix Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Tonix Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Tonix Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Tonix Pharmaceuticals 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Tonix Pharmaceuticals 並不在名單上。</p>
</div><p>While Tonix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tonix Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Geode Capital Management LLC 購買了 1,855,907 股 Tonix Pharma（NASDAQ:TNXP）的股票